Page last updated: 2024-12-04

5-methoxypsoralen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-Methoxypsoralen: A linear furanocoumarin that has phototoxic and anti-inflammatory properties, with effects similar to METHOXSALEN. It is used in PUVA THERAPY for the treatment of PSORIASIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-methoxypsoralen : A 5-methoxyfurocoumarin that is psoralen substituted by a methoxy group at position 5. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2355
CHEMBL ID24171
CHEBI ID18293
SCHEMBL ID50066
MeSH IDM0079571

Synonyms (155)

Synonym
AC-20189
5-methoxy-2h-furo[3,2-g]chromen-2-one
BRD-K12968785-001-02-6
BRD-K12968785-001-03-4
5-methoxypsoralene
4-methoxy-7h-furo[3,2-g][1]benzopyran-7-one
CHEBI:18293 ,
bergaptan
4-methoxy-furo[3,2-g]chromen-7-one
KBIO1_000529
DIVK1C_000529
NCI60_042121
SDCCGMLS-0066492.P001
SPECTRUM_000794
IDI1_000529
NCGC00017357-01
tnp00299
OPREA1_562364
NCGC00178705-01
NCGC00178705-02
D07521
pentaderm (tn)
bergaptene (dcf)
7h-furo[3, 4-methoxy-
nsc-95437
ACON1_001979
MEGXP0_000990
SPECTRUM5_000155
ACON0_000984
inchi=1/c12h8o4/c1-14-12-7-2-3-11(13)16-10(7)6-9-8(12)4-5-15-9/h2-6h,1h
7h-furo[3,2-g][1]benzopyran-7-one, 4-methoxy-
4-methoxy-7h-furo[3,2-g]chromen-7-one
NCGC00091582-01
7h-furo(3,2-g)(1)benzopyran-7-one, 4-methoxy-
ccris 4348
4-methoxy-7h-furo(3,2-g)(1)benzopyran-7-one
6-hydroxy-4-methoxy-5-benzofuranacrylic acid, gamma-lactone
5-methoxy-6,7-furanocoumarin
brn 0019560
nsc 95437
5-mop
5-methoxy psoralen
psoraderm
hsdb 3466
einecs 207-604-5
5-methoxypsoralen with ultraviolet a therapy
C01557
484-20-8
bergapten
5-methoxyfuranocoumarin ,
o-methylbergaptol
5-methoxypsoralen
bergaptene
majudin
heraclin
NSC95437 ,
5-methoxypsoralen, 99%
NCGC00091582-02
NCGC00091582-03
KBIO2_001274
KBIOGR_002055
KBIO2_003842
KBIO2_006410
KBIO3_001545
KBIOSS_001274
NINDS_000529
SPECTRUM4_001478
SPECTRUM3_000663
SPBIO_000547
SPECTRUM2_000534
SPECTRUM300546
BSPBIO_002325
NCGC00091582-04
STK333038
pentaderm
4-methoxyfuro[3,2-g]benzopyran-7-one
b2840 ,
MLS002207272
geralen
CHEMBL24171 ,
AKOS000276715
MLS002454380
smr000112435
HMS501K11
BMSE000758
HMS1923G13
bdbm50067880
4-methoxyfuro[3,2-g]chromen-7-one
5-methoxyfurano[3,2-g]chromen-2-one
tox21_303255
NCGC00256998-01
dtxcid305560
cas-484-20-8
dtxsid1025560 ,
tox21_202357
NCGC00259906-01
A827532
nsc-755877
nsc755877
pharmakon1600-00300546
HMS2268M24
S4239
CCG-39946
NCGC00017357-06
NCGC00017357-05
NCGC00017357-02
NCGC00017357-08
NCGC00017357-04
NCGC00017357-07
NCGC00017357-03
5-19-06-00004 (beilstein handbook reference)
4fvk84c92x ,
unii-4fvk84c92x
FT-0603416
5-methoxypsoralen [iarc]
5-methoxypsoralen [who-dd]
bergapten [mi]
5-methoxypsoralen [mart.]
HY-N0370
SCHEMBL50066
5-methoxy-psoralen
4-methoxy-7h-furo[3,2-g]chromen-7-one #
6-hydroxy-4-methoxy-5-benzofuranacrylic acid, .gamma.-lactone
DS-2970
AC-34208
Q-100536
AB00052148_07
AB00052148_06
mfcd00010272
4-methoxyfuro[3,2-g]benzopyrane-7-one
bergapten, analytical standard
HMS3652F19
SR-05000002173-5
SR-05000002173-2
sr-05000002173
SR-05000002173-3
SBI-0051583.P002
5-methoxypsoralen (obsol.)
4-methoxy-7h-furo[3,2-g]benzopyran-7-one
SW220008-1
DB12216
5 methoxypsoralen
Q414779
BRD-K12968785-001-11-7
BRD-K12968785-001-06-7
BCP30865
5-methoxypsoralen;heraclin
5 methoxy psoralen
5-methoxypsoralen; bergapten
gtpl12431
4-methoxyfuro(3,2-g)chromen-7-one
5-methoxypsoralen (iarc)
4-methoxy-7h-furo(3,2-g)chromen-7-one
5-methoxypsoralen (mart.)
SY051831

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Thirty-nine patients with psoriasis undergoing PUVA participated in a prospective double-blind study of acute non-phototoxic adverse effects comparing the liquid formulations of 8-methoxypsoralen (0."( Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
Ferguson, J; George, SA, 1992
)
0.28
" These studies show that the psoralens with two potential DNA-binding sites (8-MOP and 5-MOP) were more toxic than psoralens with only one photoreactive site (5-MIP and 3-CEP)."( Toxicity of 8-methoxypsoralen, 5-methoxypsoralen, 3-carbethoxypsoralen, or 5-methylisopsoralen with ultraviolet radiation in the hairless (HRA/Skh) mouse.
Davies, RE; Dunnick, JK; Forbes, PD; Iverson, WO, 1987
)
0.56
" carica have a significant toxic effect against early fourth-stage larvae of Aedes aegypti L with an lethal concentration (LC(50)) value of 10."( Immunotoxicity activity of natural furocoumarins from milky sap of Ficus carica L. against Aedes aegypti L.
Chung, IM; Kim, SJ; Moon, HI; Park, SW; Yeo, MA, 2011
)
0.37
" The phototoxicity of bergapten as a side effect should be further avoided."( Bergapten: A review of its pharmacology, pharmacokinetics, and toxicity.
Cao, Y; Dai, X; Li, X; Liang, Y; Liu, K; Lu, J; Wang, X; Xie, L; Zhang, X, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" Each subject underwent three pharmacokinetic studies after oral ingestion of 5-MOP (1."( Chronopharmacokinetics of 5-methoxypsoralen.
Agache, PG; Faivre, B; Humbert, P; Makki, S; Renaud, A; Treffel, P, 1990
)
0.58
" Differences in response are often due to the unpredictable pharmacokinetic behaviour of the drug."( Clinical pharmacokinetics of methoxsalen and other psoralens.
de Wolff, FA; Thomas, TV,
)
0.13
" The method was successfully applied to a pharmacokinetic study of eight coumarins in rats after oral administration of radix angelicae pubescentis."( Simultaneous determination of scopoletin, psoralen, bergapten, xanthotoxin, columbianetin acetate, imperatorin, osthole and isoimperatorin in rat plasma by LC-MS/MS for pharmacokinetic studies following oral administration of Radix Angelicae Pubescentis e
Chang, YX; Deng, YR; Gao, XM; Guo, XR; He, J; Li, J; Ma, L; Zhang, BL; Zhang, L; Zhang, P; Zhang, QH, 2013
)
0.39
" For the pharmacokinetic analysis of serum, the mean (SD) values obtained for the bergapten were as follows: Cmax, 228."( Pharmacokinetic studies of bergapten in dog plasma by using a LC-MS/MS method studies.
Dong, CY; Gao, Y; Liu, YZ; Zhang, X; Zhang, XM; Zhou, Y, 2013
)
0.39
" Moreover, pharmacokinetic studies showed that bergapten has higher absolute bioavailability and can cross the blood-brain barrier and has a great potential for treating brain disease, but the mechanism needs further clarification to make greater use of its ability to treat brain diseases."( Bergapten: A review of its pharmacology, pharmacokinetics, and toxicity.
Cao, Y; Dai, X; Li, X; Liang, Y; Liu, K; Lu, J; Wang, X; Xie, L; Zhang, X, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
" Drugs were selected based not only on the knowledge that the 6-hydroxylation of exogenous melatonin, its principal pathway of metabolism, is mainly mediated by hepatic CYP1A2, but also on the likelihood of the drug being concurrently administered with melatonin."( Potential drug interactions with melatonin.
Ioannides, C; Papagiannidou, E; Skene, DJ, 2014
)
0.4

Bioavailability

Single oral doses of 14C-5-methoxypsoralen (5-MOP) were fairly well absorbed but subjected to extensive first-pass metabolism, at least in rat and human.

ExcerptReferenceRelevance
" Bioavailability and phototoxicity of 5-MOP were compared."( A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.
Agache, P; Humbert, P; Khaldoun, H; Makki, S; Treffel, P, 1992
)
0.62
" Single oral doses of 14C-5-methoxypsoralen (5-MOP) to human subjects (50 mg), rats (1 mg/kg) and dogs (1 mg/kg) were fairly well absorbed but subjected to extensive first-pass metabolism, at least in rat and human."( Metabolism of the anti-psoriatic agent 5-methoxypsoralen in humans: comparison with rat and dog.
Chasseaud, LF; Forlot, P; John, BA; Wood, SG, 1992
)
0.85
" Experiments on suction blister fluids taken from patients after topical treatment with BO containing 5-MOP indicate that in comparison with water the bioavailability and thus the genotoxic effects of the compounds are decreased."( Genotoxicity of bergapten and bergamot oil in Saccharomyces cerevisiae.
Averbeck, D; Averbeck, S; Dubertret, L; Morlière, P; Young, AR, 1990
)
0.28
" With a new liquid preparation of 5-MOP we have now extended our earlier investigation on a larger clinical scale and have correlated the clinical response with the bioavailability of the drug."( 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
Hönigsmann, H; Ortel, B; Rappersberger, K; Tanew, A, 1988
)
1.72
" The bioavailability of 5-MOP was significantly lower than that of 8-MOP in all tissues analyzed."( Kinetics of 8-methoxypsoralen and 5-methoxypsoralen distribution in guinea pig serum, epidermis and ocular lens.
Giles, A; Kornhauser, A; Wamer, W, 1987
)
0.55
" Bioavailability and phototoxicity were compared."( Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen.
Cormane, RH; Siddiqui, AH; Stolk, LM; Westerhof, W, 1985
)
0.5
"The bioavailability of two galenic formulations of 5-methoxypsoralen (5-MOP) is described."( [5-Methoxypsoralen: bioavailability and pharmacokinetics].
Mascher, H; Nitsche, V, 1982
)
1.43
" The food had a dramatic effect on the bioavailability of 5-MOP."( Food-induced increase in bioavailability of 5-methoxypsoralen.
Berg, M; Ehrsson, H; Eksborg, S; Ros, AM; Wallin, I, 1994
)
0.55
" However, the poor water solubility, low stability and limited bioavailability have prevented the use of BEO in cancer therapy."( Anticancer activity of liposomal bergamot essential oil (BEO) on human neuroblastoma cells.
Britti, D; Carafa, M; Celia, C; Di Marzio, L; Locatelli, M; Morittu, VM; Navarra, M; Paolino, D; Trapasso, E; Ventura, CA; Wolfram, J, 2013
)
0.39
" Moreover, pharmacokinetic studies showed that bergapten has higher absolute bioavailability and can cross the blood-brain barrier and has a great potential for treating brain disease, but the mechanism needs further clarification to make greater use of its ability to treat brain diseases."( Bergapten: A review of its pharmacology, pharmacokinetics, and toxicity.
Cao, Y; Dai, X; Li, X; Liang, Y; Liu, K; Lu, J; Wang, X; Xie, L; Zhang, X, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" The high incidence of adverse effects suggests that current dosage recommendations be reviewed."( Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
Ferguson, J; George, SA, 1992
)
0.28
" When administered in the same dosage as 8-MOP, 5-MOP turned out to be significantly less effective; however, by doubling the oral dosage, comparable results in terms of clearing of psoriasis were obtained."( 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
Hönigsmann, H; Ortel, B; Rappersberger, K; Tanew, A, 1988
)
1.72
" Dose-response curves for 5-MOP and 8-MOP obtained under standardized conditions demonstrated a linear relationship between the diameter of growth inhibition zones and the logarithm of the psoralen concentration in the range from 1 to 400 micrograms/ml."( The Candida phototoxicity test. The sensitivity of different strains and species of Candida, standardization attempts and analysis of the dose-response curves for 5- and 8-methoxypsoralen.
Knudsen, EA, 1985
)
0.27
" All test groups developed atypical squamous papillomas in direct proportion to the dosage of UVA radiation received."( Psoralen-containing sunscreen is tumorigenic in hairless mice.
Cartwright, LE; Walter, JF, 1983
)
0.27
" A suspension in soft gelatine capsules was tested against a micronized powder in hard gelatine capsules on six volunteers, both in a dosage of 40 mg."( [5-Methoxypsoralen: bioavailability and pharmacokinetics].
Mascher, H; Nitsche, V, 1982
)
1.17
" To obtain dose-response relations the drug-induced effects on peak P'K and on the steady state value, kinfinity, were measured."( Effects of three alkoxypsoralens on voltage gated ion channels in Ranvier nodes.
Düring, T; Gerst, F; Hänsel, W; Koppenhöfer, E; Wulff, H, 2000
)
0.31
" Seventy-two hours after UVA exposure minimal phototoxic doses (MPD) were defined visually and the intensity of the erythema response was also assessed by using a narrowband spectrophotometer The MPD and the dose-response curves for erythema response of the gels and creams were compared with those of the bath."( Phototoxicity of new psoralen-containing gels and creams versus bath PUVA.
Leenutaphong, V; Nimkulrat, P; Sudtim, S, 2005
)
0.33
" The slope of the dose-response curve for erythema of this preparation also significantly corresponded to that of the bath solution."( Phototoxicity of new psoralen-containing gels and creams versus bath PUVA.
Leenutaphong, V; Nimkulrat, P; Sudtim, S, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
hepatoprotective agentAny compound that is able to prevent damage to the liver.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
psoralensA furanocoumarin with a 7H-furo[3,2-g]chromen-7-one skeleton and its substituted derivatives thereof.
5-methoxyfurocoumarinA furanocoumarin which bears a methoxy group at position 5.
organic heterotricyclic compoundAn organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
linear furanocoumarin biosynthesis120
linear furanocoumarin biosynthesis221
Melatonin metabolism and effects016
Linear furanocoumarin biosynthesis015

Protein Targets (61)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
RAR-related orphan receptor gammaMus musculus (house mouse)Potency23.01320.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency19.33120.000714.592883.7951AID1259369
AR proteinHomo sapiens (human)Potency13.71970.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743035; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency33.19130.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.98110.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency7.34070.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency35.09110.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency28.24360.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency22.17610.001530.607315,848.9004AID1224841
pregnane X nuclear receptorHomo sapiens (human)Potency38.69690.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.78730.000229.305416,493.5996AID743069; AID743075; AID743077; AID743078; AID743079; AID743080
aryl hydrocarbon receptorHomo sapiens (human)Potency0.03670.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency21.50270.001723.839378.1014AID743083
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency1.99530.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency3.16230.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency5.01190.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency9.90570.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency42.16320.000627.21521,122.0200AID651741
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.00000.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency5.01190.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency44.66841.995325.532750.1187AID624287
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A1Homo sapiens (human)IC50 (µMol)0.08000.00791.24789.9000AID1411739
Cytochrome P450 1A1Homo sapiens (human)Ki0.06000.01200.94693.8000AID1411739
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)0.09000.00011.774010.0000AID1411740
Cytochrome P450 1A2Homo sapiens (human)Ki0.06000.00561.15349.0000AID1411740
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)10.00000.00011.753610.0000AID1411745
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)10.00000.00002.015110.0000AID1411742
Cytochrome P450 2A6Homo sapiens (human)Ki12.00000.00561.52717.5000AID589223
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)10.00000.00002.800510.0000AID1411743
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)13.80000.00002.37899.7700AID744458
Potassium voltage-gated channel subfamily A member 3Homo sapiens (human)IC50 (µMol)101.00000.00203.19698.0000AID420267
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)10.00000.00002.398310.0000AID1411744
Beta-secretase 1Homo sapiens (human)IC50 (µMol)500.00000.00061.619410.0000AID637774
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)15.30000.00130.86969.9000AID1411741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
dual specificity tyrosine-phosphorylation-regulated kinase 1ARattus norvegicus (Norway rat)AC501.48900.00564.693226.6940AID588345
ATP-dependent translocase ABCB1Homo sapiens (human)EC200 (µMol)0.05000.03500.10630.3000AID678837
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (213)

Processvia Protein(s)Taxonomy
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
potassium ion transportPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
regulation of dopamine secretionPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
neuronal action potentialPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
sensory perception of painPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
optic nerve structural organizationPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
cerebral cortex developmentPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
corpus callosum developmentPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
regulation of circadian sleep/wake cycle, non-REM sleepPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
regulation of postsynaptic membrane potentialPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
regulation of presynaptic membrane potentialPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
potassium ion transportPotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
potassium ion transportPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
optic nerve developmentPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
corpus callosum developmentPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
potassium ion transportPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
response to hypoxiaPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
Notch signaling pathwayPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
response to mechanical stimulusPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
response to organic substancePotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
regulation of vasoconstrictionPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
response to hydrogen peroxidePotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
regulation of potassium ion transportPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
regulation of insulin secretionPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
negative regulation of cytosolic calcium ion concentrationPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
response to hyperoxiaPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
membrane hyperpolarizationPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
membrane repolarization during bundle of His cell action potentialPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
membrane repolarization during SA node cell action potentialPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
membrane repolarization during atrial cardiac muscle cell action potentialPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cyclePotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
positive regulation of myoblast proliferationPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
potassium ion transportPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
response to toxic substancePotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
response to light intensityPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
response to auditory stimulusPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
response to aminePotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
cerebellum developmentPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
optic nerve developmentPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
globus pallidus developmentPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
corpus callosum developmentPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
response to potassium ionPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
protein tetramerizationPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
response to fibroblast growth factorPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
regulation of presynaptic membrane potentialPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
response to nerve growth factorPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
proteolysisBeta-secretase 1Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 1Homo sapiens (human)
response to lead ionBeta-secretase 1Homo sapiens (human)
protein processingBeta-secretase 1Homo sapiens (human)
amyloid-beta formationBeta-secretase 1Homo sapiens (human)
amyloid precursor protein catabolic processBeta-secretase 1Homo sapiens (human)
positive regulation of neuron apoptotic processBeta-secretase 1Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painBeta-secretase 1Homo sapiens (human)
prepulse inhibitionBeta-secretase 1Homo sapiens (human)
cellular response to copper ionBeta-secretase 1Homo sapiens (human)
cellular response to manganese ionBeta-secretase 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionBeta-secretase 1Homo sapiens (human)
signaling receptor ligand precursor processingBeta-secretase 1Homo sapiens (human)
cellular response to amyloid-betaBeta-secretase 1Homo sapiens (human)
amyloid fibril formationBeta-secretase 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
startle responsePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
regulation of muscle contractionPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuroblast proliferationPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
protein localizationPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cell communication by electrical couplingPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
magnesium ion homeostasisPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuronal action potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
optic nerve developmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
hippocampus developmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cerebral cortex developmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
corpus callosum developmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuronal signal transductionPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuromuscular processPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of touchPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
protein homooligomerizationPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
regulation of postsynaptic membrane potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
axon developmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cellular response to magnesium ionPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
regulation of presynaptic membrane potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
action potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (84)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
potassium channel activityPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
outward rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
kinesin bindingPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
voltage-gated monoatomic ion channel activityPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
outward rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
signaling receptor bindingPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
outward rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
protein kinase bindingPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
alpha-actinin bindingPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
voltage-gated potassium channel activity involved in bundle of His cell action potential repolarizationPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
voltage-gated potassium channel activity involved in SA node cell action potential repolarizationPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
kinesin bindingPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
transmembrane transporter bindingPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
amyloid-beta bindingBeta-secretase 1Homo sapiens (human)
endopeptidase activityBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 1Homo sapiens (human)
protein bindingBeta-secretase 1Homo sapiens (human)
peptidase activityBeta-secretase 1Homo sapiens (human)
beta-aspartyl-peptidase activityBeta-secretase 1Homo sapiens (human)
enzyme bindingBeta-secretase 1Homo sapiens (human)
protein serine/threonine kinase bindingBeta-secretase 1Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
disordered domain specific bindingPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (58)

Processvia Protein(s)Taxonomy
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membranePotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
lamellipodiumPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
axonPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
dendritePotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
lamellipodium membranePotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
neuronal cell body membranePotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
paranodal junctionPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
presynaptic membranePotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
axon initial segmentPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
perikaryonPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
axon terminusPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
juxtaparanode region of axonPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
calyx of HeldPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
postsynaptic membranePotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
glutamatergic synapsePotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
axon terminusPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
dendritePotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
membranePotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
juxtaparanode region of axonPotassium voltage-gated channel subfamily A member 2Homo sapiens (human)
cytosolPotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
intracellular membrane-bounded organellePotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
axon terminusPotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
potassium channel complexPotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
membranePotassium voltage-gated channel subfamily A member 6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
presynaptic membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
calyx of HeldPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
postsynaptic membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
glutamatergic synapsePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
axonPotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
membranePotassium voltage-gated channel subfamily A member 3Homo sapiens (human)
caveolaPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
Golgi apparatusPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
intercalated discPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
Z discPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
membrane raftPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
intracellular canaliculusPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
potassium channel complexPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
intercalated discPotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
membranePotassium voltage-gated channel subfamily A member 5Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
axolemmaPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
neuronal cell body membranePotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
calyx of HeldPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
neuronal cell body membranePotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
postsynaptic membranePotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
presynaptic membranePotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
dendrite membranePotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
axon terminusPotassium voltage-gated channel subfamily C member 1Homo sapiens (human)
lysosomeBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
early endosomeBeta-secretase 1Homo sapiens (human)
late endosomeBeta-secretase 1Homo sapiens (human)
multivesicular bodyBeta-secretase 1Homo sapiens (human)
endoplasmic reticulum lumenBeta-secretase 1Homo sapiens (human)
Golgi apparatusBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
synaptic vesicleBeta-secretase 1Homo sapiens (human)
cell surfaceBeta-secretase 1Homo sapiens (human)
endosome membraneBeta-secretase 1Homo sapiens (human)
membraneBeta-secretase 1Homo sapiens (human)
axonBeta-secretase 1Homo sapiens (human)
dendriteBeta-secretase 1Homo sapiens (human)
neuronal cell bodyBeta-secretase 1Homo sapiens (human)
membrane raftBeta-secretase 1Homo sapiens (human)
recycling endosomeBeta-secretase 1Homo sapiens (human)
Golgi-associated vesicle lumenBeta-secretase 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
endoplasmic reticulumPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cytosolPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
apical plasma membranePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cell junctionPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
dendritePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
cytoplasmic vesiclePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
paranode region of axonPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
presynaptic membranePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
axon initial segmentPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
perikaryonPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
axon terminusPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
juxtaparanode region of axonPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
calyx of HeldPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
synapsePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
postsynaptic membranePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
anchoring junctionPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
glutamatergic synapsePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
dendritePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
paranode region of axonPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
membranePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
synapsePotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
juxtaparanode region of axonPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
neuronal cell bodyPotassium voltage-gated channel subfamily A member 1Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (130)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID95610Selectivity of K+ current blockade given by Bk/BNa in Xenopus laevis1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID1103220Phytotoxicity against Lactuca sativa cv. Burpee's Iceberg (lettuce) assessed as cellular leakage at 100 uM measured after incubation over 18 hr in darkness and 24 hr in light by spectrophotometry relative to control2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID334652Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID334654Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID1195522Inhibition of PTP1B (unknown origin) at 20 ug/ml using pNPP substrate measured after 3 mins by colorimetric assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
PTP1B inhibitors from stems of Angelica keiskei (Ashitaba).
AID162564Photobinding to Poly(dA-dT)-Poly(dA-dT)-DNA in dark, determined by the shift of thermal transition temperature1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID401513Effect on compound 48/80-induced histamine level in ddY mouse peritoneal cavity fluid assessed as histamine release at 10 mg/kg, ip administered 15 mins before compound 48/80 challenge measured after 10 mins by fluorometric assay relative to control1997Journal of natural products, Mar, Volume: 60, Issue:3
Histamine-release effectors from Angelica dahurica var. dahurica root.
AID1411741Inhibition of human recombinant CYP1B1 expressed in HEK293 cells using 7-ethoxyresorufin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID1411733Inhibition of recombinant human CYP1B1 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 7-ethoxyresorufin substrate by EROD assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID724354Antioxidant activity assessed as inhibition of AAPH-induced linoleic acid lipid peroxidation at 100 uM by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID334651Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID88691The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated)1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: synthesis, DNA interaction, and antiproliferative activity.
AID1615746Cytotoxicity against human HepG2 cells assessed as cell viability at 10 uM incubated for 1 hr by EZ-Cytox cell viability assay2019Journal of natural products, 09-27, Volume: 82, Issue:9
Furanocoumarins from the Roots of
AID1411735Inhibition of recombinant human CYP3A4 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using dibenzylfluorescein substrate by EROD assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID334657Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID637775Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate at 500 uM after 60 mins by fluorescence quenching assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor.
AID1411740Inhibition of human recombinant CYP1A2 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID1411734Inhibition of recombinant human CYP2D6 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 7-ethoxy-methyloxy-3-cyanocoumarin substrate by EROD assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID1103222Phytotoxicity against Lactuca sativa cv. Burpee's Iceberg (lettuce) assessed as blunt root tips at 10 uM after 7 days by spectrophotometry relative to control2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID724349Cytotoxicity against human 1BR3 cells assessed as cell viability at 20 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID467954Antiproliferative activity against mouse EAC cells assessed as ratio of ID50 of compound to ID50 of 8-methoxypsoralen2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Scoring function for DNA-drug docking of anticancer and antiparasitic compounds based on spectral moments of 2D lattice graphs for molecular dynamics trajectories.
AID637774Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate after 60 mins by fluorescence quenching assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor.
AID77719The compound was tested for photo antiproliferative activity and ability to induce erythema on guinea pig skin; +++ = strong (without edema)1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: synthesis, DNA interaction, and antiproliferative activity.
AID724351Cytotoxicity against human 1BR3 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID724348Cytotoxicity against human 1BR3 cells assessed as cell viability at 100 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID1355969Cytotoxicity against human MDA-MB-231 cells by MTT assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Bioactive Phenolic Components from the Twigs of Atalantia buxifolia.
AID132695Inhibitory activity against LPS-induced NO production in mouse peritoneal macrophages was evaluated1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Hepatoprotective and nitric oxide production inhibitory activities of coumarin and polyacetylene constituents from the roots of Angelica furcijuga.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1615748Inhibition of H2O2-induced ROS accumulation in human HepG2 cells assessed as ROS generation at 10 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 30 mins by H2DCFDA staining based flow cytometry (Rvb = 100 +/- 11.53%)2019Journal of natural products, 09-27, Volume: 82, Issue:9
Furanocoumarins from the Roots of
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID95609K+ channel blocking activity as blockade at 25 uM in Xenopus laevis Ranvier nodes1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID334662Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 150 ug/plate after 72 hrs
AID334650Toxicity in Salmonella Typhimurium T98 at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID1411737Inhibition of recombinant human CYP2C19 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID334659Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID334655Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID1102096Antifungal activity against Diaporthe ampelina assessed as growth inhibition at 30 to 300 uM after 120 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID88690The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: synthesis, DNA interaction, and antiproliferative activity.
AID451813Inhibition of calf thymus DNA topoisomerase 1 assessed as pUC19 DNA relaxation by gel electrophoresis2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Furanocoumarins: novel topoisomerase I inhibitors from Ruta graveolens L.
AID334660Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 600 ug/plate after 72 hrs
AID1091219Insecticidal activity against Bactrocera oleae exposed to compound for 12 hr assessed as insect mortality measured 72 hr post dose by petri dish exposure bioassay (Rvb = 2 +/- 2%)2008Journal of agricultural and food chemistry, Jul-23, Volume: 56, Issue:14
Isolation and identification of insecticidal components from Citrus aurantium fruit peel extract.
AID94397Blockade of peak Kv1.3 potassium currents1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID1103221Phytotoxicity against Lactuca sativa cv. Burpee's Iceberg (lettuce) assessed as unbranched root tips at 10 uM after 7 days by spectrophotometry relative to control2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID666151Inhibition of PA endonuclease at 1 uM2011PloS one, , Volume: 6, Issue:5
Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts.
AID1103219Phytotoxicity against Agrostis stolonifera assessed as mortality at 333 uM after 12 days2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID85578Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Pyrrolo[2,3-h]quinolinones: synthesis and photochemotherapic activity.
AID589223Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID420267Inhibition of Kv1.3 potassium channel expressed in mouse L929 cells by whole cell patch clamp2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3.
AID1411745Inhibition of human recombinant CYP3A4 expressed in HEK293 cells using dibenzylfluorescein substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID81632The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: synthesis, DNA interaction, and antiproliferative activity.
AID358548Cytotoxicity against human HSC2 cells2001Journal of natural products, Jan, Volume: 64, Issue:1
Benzophenones and xanthones with isoprenoid groups from Cudrania cochinchinensis.
AID1355968Cytotoxicity against human HepG2 cells by MTT assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Bioactive Phenolic Components from the Twigs of Atalantia buxifolia.
AID589180Mechanism based inhibition of human cytochrome P450 2B6, partition ratio (value refers to P450 expressed in baculovirus infected insect cells)2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID420266Selectivity for Kv1.3 potassium channel over Kv1.5 potassium channel2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3.
AID95615Blockade of peak K+ currents against Kv1.5 gene1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID724355Inhibition of soybean LOX using sodium linoleate as substrate by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID1103216Phytotoxicity against Allium cepa (onion) assessed as inhibition of mitosis in root tips at 100 uM measured on day 7 of compound treatment by microscopy2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1411747Selectivity index, ratio of IC50 for inhibition of human recombinant CYP1B1 expressed in HEK293 cells by fluorescence assay to IC50 for inhibition of human recombinant CYP1A1 expressed in HEK293 cells by fluorescence assay2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID81634The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated)1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: synthesis, DNA interaction, and antiproliferative activity.
AID211479Compound was tested for in vitro phototoxicity against nauplii of Artemia salina in daylight1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID334661Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 300 ug/plate after 72 hrs
AID135391Inhibitory activity from the roots of Angelica furcijuga on LPS-induced NO production in mouse peritoneal macrophages was evaluated at 100 uM1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Hepatoprotective and nitric oxide production inhibitory activities of coumarin and polyacetylene constituents from the roots of Angelica furcijuga.
AID1411732Inhibition of recombinant human CYP1A2 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID724347Cytotoxicity against human 1BR3 cells assessed as cell viability at 50 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID1195523Inhibition of PTP1B (unknown origin) using pNPP substrate measured after 3 mins by colorimetric assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
PTP1B inhibitors from stems of Angelica keiskei (Ashitaba).
AID1411738Inhibition of human recombinant CYP1A1 expressed in HEK293 cells at 10 uM using 7-ethoxyresorufin substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID180280Inhibitory activity against D-GalN-induced cytotoxicity in rat hepatocytes1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Hepatoprotective and nitric oxide production inhibitory activities of coumarin and polyacetylene constituents from the roots of Angelica furcijuga.
AID724357Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID744458Inhibition of MAO-A (unknown origin)2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
AID1102102Antifungal activity against Phomopsis obscurans assessed as growth inhibition at 30 uM after 120 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID420264Inhibition of Kv1.5 potassium channel by whole cell patch clamp2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3.
AID1615747Hepatoprotective activity against H2O2-induced cell death in human HepG2 cells assessed as cell viability at 10 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 24 hrs by EZ-Cytox cell viability assay (Rvb = 43.9 +/- 5.25%)2019Journal of natural products, 09-27, Volume: 82, Issue:9
Furanocoumarins from the Roots of
AID20846Compound was tested for production of single oxygen, measured as decrease in absorbance of N,N-dimethyl-p-nitrosoaniline (RNO) at 440 nm after 5 hr of UV-A irradiation1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID211478Compound was tested for in vitro phototoxicity against nauplii of Artemia salina after UV-irradiation1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID1103223Phytotoxicity against Lactuca sativa cv. Burpee's Iceberg (lettuce) assessed as reduction in radical length at 10 uM after 7 days by spectrophotometry relative to control2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID1411739Inhibition of human recombinant CYP1A1 expressed in HEK293 cells using 7-ethoxyresorufin substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID95617Blockade of peak K+ currents against Kv1.6 gene1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID1411730Inhibition of recombinant human CYP1A1 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 7-ethoxyresorufin substrate by EROD assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID1411742Inhibition of human recombinant CYP2D6 expressed in HEK293 cells using 7-ethoxy-methyloxy-3-cyanocoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID95613Blockade of peak K+ currents against Kv1.2 gene1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID358550Selectivity ratio CC50 for HGF to CC50 for human HSC-2 cells2001Journal of natural products, Jan, Volume: 64, Issue:1
Benzophenones and xanthones with isoprenoid groups from Cudrania cochinchinensis.
AID678837TP_TRANSPORTER: increase uptake (Vinblastine: 0.01 uM) in Caco-2 cells2000British journal of pharmacology, Jul, Volume: 130, Issue:6
Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4.
AID39075Photoinduced dose modification against nauplii of Artemia salina1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID1411743Inhibition of human recombinant CYP2C9 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID1091220Insecticidal activity against Bactrocera oleae exposed to 0.45 ug/cm2 compound for 12 hr assessed as insect mortality measured 72 hr post dose by petri dish exposure bioassay (Rvb = 2 +/- 2%)2008Journal of agricultural and food chemistry, Jul-23, Volume: 56, Issue:14
Isolation and identification of insecticidal components from Citrus aurantium fruit peel extract.
AID95620Blockade of peak K+ currents against Kv3.1 gene1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID1102110Stimulation of Colletotrichum gloeosporioides growth at 30 to 300 uM after 48 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID401514Effect on compound 48/80-induced histamine level in ddY mouse peritoneal cavity fluid assessed as histamine release at 25 mg/kg, ip administered 15 mins before compound 48/80 challenge measured after 10 mins by fluorometric assay relative to control1997Journal of natural products, Mar, Volume: 60, Issue:3
Histamine-release effectors from Angelica dahurica var. dahurica root.
AID1102107Fungistatic activity against Fusarium solani assessed as growth inhibition2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID334658Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID1411736Inhibition of recombinant human CYP2C9 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 3-cyano-7-ethoxycoumarin substrate by EROD assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID682241TP_TRANSPORTER: inhibition of Fexofenadine uptake (Fexofenadine: 1? uM, 5-Methoxypsoralen: 50 uM) in Oatp3-expressing HeLa cells2002Clinical pharmacology and therapeutics, Jan, Volume: 71, Issue:1
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.
AID358549Cytotoxicity against HGF cells2001Journal of natural products, Jan, Volume: 64, Issue:1
Benzophenones and xanthones with isoprenoid groups from Cudrania cochinchinensis.
AID1355970Cytotoxicity against human A549 cells by MTT assay2018Journal of natural products, 07-27, Volume: 81, Issue:7
Bioactive Phenolic Components from the Twigs of Atalantia buxifolia.
AID85577Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Pyrrolo[2,3-h]quinolinones: synthesis and photochemotherapic activity.
AID183726Inhibitory activity against D-GalN-induced cytotoxicity in rat hepatocytes at 100 uM1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
Hepatoprotective and nitric oxide production inhibitory activities of coumarin and polyacetylene constituents from the roots of Angelica furcijuga.
AID744459Inhibition of mouse brain monoamine oxidase2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
AID451810Inhibition of calf thymus DNA topoisomerase 1 assessed as pUC19 DNA relaxation at 10 uM by gel electrophoresis2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Furanocoumarins: novel topoisomerase I inhibitors from Ruta graveolens L.
AID95611Blockade of peak K+ currents against Kv1.1 gene1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID666150Inhibition of PA endonuclease at 10 uM2011PloS one, , Volume: 6, Issue:5
Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts.
AID1102112Stimulation of Colletotrichum acutatum growth at 30 uM after 48 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID162563Photobinding to Poly(dA-dT)-Poly(dA-dT)-DNA after UV-A irradiation1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID724350Cytotoxicity against human 1BR3 cells assessed as cell viability at 1 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID334653Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID334656Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID724358Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID1411744Inhibition of human recombinant CYP2C19 expressed in HEK293 cells using 3-cyano-7-ethoxycoumarin substrate substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by fluorescence assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID85579Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Pyrrolo[2,3-h]quinolinones: synthesis and photochemotherapic activity.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (329)

TimeframeStudies, This Drug (%)All Drugs %
pre-199077 (23.40)18.7374
1990's85 (25.84)18.2507
2000's64 (19.45)29.6817
2010's81 (24.62)24.3611
2020's22 (6.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.86 (24.57)
Research Supply Index5.91 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (4.26%)5.53%
Reviews16 (4.55%)6.00%
Case Studies14 (3.98%)4.05%
Observational0 (0.00%)0.25%
Other307 (87.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Comparison of Fumaric Acid Ester-PUVA (FAE-PUVA) Versus Acitretin-PUVA (Re-PUVA) in Pustular Palmoplantar Psoriasis,a Prospective, Randomized, Controlled, Single-blinded Study [NCT00811005]Phase 320 participants (Anticipated)Interventional2008-10-31Active, not recruiting
UVA1 Phototherapy Versus 5-MOP UVA Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis [NCT00533195]Phase 320 participants (Anticipated)Interventional2007-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]